Evidence map›Paper›PMID 30615985›Full record

ReviewDiabetes & metabolism2019

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

V R Aroda, A Ahmann, B Cariou, F Chow, M J Davies, E Jódar, R Mehta, V Woo, I Lingvay

7 registry-linked trialsOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01720446. Cited by 131 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 10 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01720446 phase3completed

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)

Ran2013Enrolled3,297Registered outcomes16Posted comparisons54ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide
PMID 31167654PMID 30851070PMID 27633186PMID 29178519PMID 29907893other papers from this trial
Open the trial in the graph
NCT01885208 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

Ran2013Enrolled813Registered outcomes6Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2Armsexenatide, semaglutide
PMID 29862621PMID 29246950PMID 29748996PMID 30865526PMID 30047216PMID 29687620PMID 29766634PMID 30535837PMID 30938762PMID 29907893other papers from this trial
Open the trial in the graph
NCT01930188 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)

Ran2013Enrolled1,231Registered outcomes6Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide, Sitagliptin
PMID 29862621PMID 29764222PMID 28385659PMID 29748996PMID 30865526PMID 29766634PMID 30938762PMID 29907893other papers from this trial
Open the trial in the graph
NCT02054897 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Ran2014Enrolled388Registered outcomes6Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide
PMID 29862621PMID 28110911PMID 29748996PMID 30865526PMID 30047216PMID 29687620PMID 29766634PMID 30938762PMID 29907893other papers from this trial
Open the trial in the graph
NCT02128932 phase3completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Ran2014Enrolled1,089Registered outcomes8Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsInsulin glargine, semaglutide
PMID 29862621PMID 28526920PMID 28344112PMID 30865526PMID 29687620PMID 29766634other papers from this trial
Open the trial in the graph
NCT02305381 phase3completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Ran2014Enrolled397Registered outcomes8Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide
PMID 29862621PMID 30865526PMID 29688502PMID 29687620PMID 29766634other papers from this trial
Open the trial in the graph
NCT02648204 phase3completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Ran2016Enrolled1,201Registered outcomes28Posted comparisons6ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsDulaglutide, semaglutide
PMID 29764222PMID 29246950PMID 30362224PMID 30865526PMID 29397376PMID 31168765PMID 29557057PMID 30927241other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 10 syntheses or guidelines pooled it, 264 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025 · on this map
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Clinical Pharmacokinetics of Semaglutide: A Systematic Review.Drug design, development and therapy · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 7 countries.

V R ArodaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: varoda@bwh.harvard.edu.
A AhmannHarold Schnitzer Diabetes Health Center at Oregon Health and Science University, Portland, OR, USA. Electronic address: ahmanna@ohsu.edu.
B CariouL'institut du thorax, CHU de Nantes, CIC 1413, Inserm, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.
F ChowPrince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. Electronic address: b410773@mailserv.cuhk.edu.hk.
M J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK. Electronic address: melanie.davies@uhl-tr.nhs.uk.
E JódarHospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain. Electronic address: esteban.jodar@gmail.com.
R MehtaUnidad de Investigacón en Enfermedades Metabolicas, Departamento de Endocrinologia y Metablismo, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" Mexico City, Mexico. Electronic address: roopamehta@yahoo.com.
V WooSection of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada. Electronic address: vwoo3@shaw.ca.
I LingvayUT Southwestern Medical Center, Dallas, TX, USA. Electronic address: Ildiko.Lingvay@UTSouthwestern.edu.
Centre Hospitalier Universitaire de Nantes · FRChinese University of Hong Kong · CNHarvard University · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXOregon Health & Science University · USSouthwestern Medical Center · USUniversidad Europea de Madrid · ESUniversity of Leicester · GBUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Glucagon-Like PeptidesHumansHypoglycemic AgentsIncretinsInjections, SubcutaneousSemaglutideTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsIncretinsSemaglutideCardiovascularEfficacyGlucagon-like peptide-1 receptor agonistSemaglutide, SUSTAINType 2 diabetes

Identifiers

PMID30615985
OpenAlexW2908397509

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.